Recent standardization of treatment strategy for pancreatic neuroendocrine tumors

World Journal of Gastroenterology

Volumn 16, Issue 36, 2010, Pages 4519-4525

  Imamura, Masayuki ^a  

^a KANSAI DENRYOKU HOSPITAL   (Japan)

Author keywords

Gastrinoma; Glucagonoma; Insulinoma; Multiple endocrine neoplasia type 1; Octreotide; Pancreas preserving total duodenectomy; Pancreatic neuroendocrine tumors; Selective arterial secretagogue injection test; Somatostatin receptor scintigraphy

Indexed keywords

C PEPTIDE; CALCIUM; CISPLATIN; ETOPOSIDE; FLUOROURACIL; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OCTREOTIDE; PROTEIN TYROSINE KINASE INHIBITOR; SECRETIN; SOMATOSTATIN RECEPTOR; STREPTOZOCIN;

ARTICLE; CHEMOEMBOLIZATION; CHEMOTHERAPY; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; GASTRINOMA; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GLUCAGONOMA; HISTOPATHOLOGY; HUMAN; INCIDENCE; INSULINOMA; LABORATORY TEST; LIVER METASTASIS; LIVER RESECTION; MULTIPLE ENDOCRINE NEOPLASIA; NEUROENDOCRINE TUMOR; PANCREATIC NEUROENDOCRINE TUMOR; PREVALENCE; PROGNOSIS; RADIOFREQUENCY ABLATION; RECURRENT PEPTIC ULCER; SCINTIGRAPHY; SELECTIVE ARTERIAL SECRETAGOGUE INJECTION TEST; SOMATOSTATIN RECEPTOR SCINTIGRAPHY; STANDARDIZATION; TUMOR CLASSIFICATION; TUMOR LOCALIZATION; ZOLLINGER ELLISON SYNDROME;

EID: 77957578406     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i36.4519     Document Type: Article

References (54)

1. Imamura M, Takahashi K, Adachi H, Minematsu S, Shimada Y, Naito M, Suzuki T, Tobe T, Azuma T. Usefulness of selective arterial secretin injection test for localization of gastrinoma in the Zollinger-Ellison syndrome. Ann Surg 1987; 205: 230-239
2. Krenning EP, Kwekkeboom DJ, Oei HY, de Jong RJ, Dop FJ, Reubi JC, Lamberts SW. Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. An overview of European results. Ann N Y Acad Sci 1994; 733: 416-424
3. Soga J. The term carcinoid is a misnomer: the evidence based on local invasion. J Exp Clin Cancer Res 2009; 28: 15
4. Klöppel G. Tumour biology and histopathology of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21: 15-31
5. Plöckinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder WW, Goede A, Caplin M, Oberg K, Reubi JC, Nilsson O, Delle Fave G, Ruszniewski P, Ahlman H, Wiedenmann B. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004; 80: 394-424
6. Oberg K, Astrup L, Eriksson B, Falkmer SE, Falkmer UG, Gustafsen J, Haglund C, Knigge U, Vatn MH, Välimäki M. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I-general overview. Acta Oncol 2004; 43: 617-625
7. Tomassetti P, Campana D, Piscitelli L, Casadei R, Nori F, Brocchi E, Santini D, Pezzilli R, Corinaldesi R. Endocrine tumors of the ileum: factors correlated with survival. Neuroendocrinology 2006; 83: 380-386
8. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008; 9: 61-72
9. Ito T, Tanaka M, Sasano H, Osamura YR, Sasaki I, Kimura W, Takano K, Obara T, Ishibashi M, Nakao K, Doi R, Shimatsu A, Nishida T, Komoto I, Hirata Y, Imamura M, Kawabe K, Nakamura K. Preliminary results of a Japanese nationwide survey of neuroendocrine gastrointestinal tumors. J Gastroenterol 2007; 42: 497-500
10. Ito T, Sasano H, Tanaka M, Osamura RY, Sasaki I, Kimura W, Takano K, Obara T, Ishibashi M, Nakao K, Doi R, Shimatsu A, Nishida T, Komoto I, Hirata Y, Nakamura K, Igarashi H, Jensen RT, Wiedenmann B, Imamura M. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 2010; 45: 234-243
11. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after carcinoid: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072
12. Grant CS. Insulinoma. In: Doherty GM, Skogseid B, editors. Surgical Endocrinology. Philadelphia: Lippincott Williums & Wilkins, 2001: 345-360
13. Service FJ, O'Brien PC, Kao PC, Young WF Jr. C-peptide suppression test: effects of gender, age, and body mass index; implications for the diagnosis of insulinoma. J Clin Endocrinol Metab 1992; 74: 204-210
14. Berna MJ, Hoffmann KM, Serrano J, Gibril F, Jensen RT. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore) 2006; 85: 295-330
15. Berna MJ, Hoffmann KM, Long SH, Serrano J, Gibril F, Jensen RT. Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine (Baltimore) 2006; 85: 331-364
16. Imamura M, Shimada Y, Kato M, Doi R, Okada N, Hashimoto M. Usefulness of selective arterial calcium injection test and secretin test in patients with insulinoma. J Hep Bil Pancr Surg 1994; 1: 530-534
17. Imamura M, Hattori Y, Nishida O, Honda T, Shimada Y, Miyahara T, Wagata T, Baba N, Tobe T. Unresponsiveness of insulinoma cells to secretin: significance of the secretin test in patients with insulinoma. Pancreas 1990; 5: 467-473
18. Isenberg JI, Walsh JH, Passaro E Jr, Moore EW, Grossman MI. Unusual effect of secretin on serum gastrin, serum calcium, and gastric acid secretion in a patient with suspected Zollinger-Ellison syndrome. Gastroenterology 1972; 62: 626-631
19. Hattori Y, Imamura M, Tobe T. Gastrin release from antral G cells stimulated with secretin. Am J Gastroenterol 1992; 87: 195-200
20. Imamura M, Komoto I, Ota S. Changing treatment strategy for gastrinoma in patients with Zollinger-Ellison syndrome. World J Surg 2006; 30: 1-11
21. Imamura M, Takahashi K, Isobe Y, Hattori Y, Satomura K, Tobe T. Curative resection of multiple gastrinomas aided by selective arterial secretin injection test and intraoperative secretin test. Ann Surg 1989; 210: 710-718
22. Turner JJ, Wren AM, Jackson JE, Thakker RV, Meeran K. Localization of gastrinomas by selective intra-arterial calcium injection. Clin Endocrinol (Oxf) 2002; 57: 821-825
23. Alexander HR, Fraker DL, Norton JA, Bartlett DL, Tio L, Benjamin SB, Doppman JL, Goebel SU, Serrano J, Gibril F, Jensen RT. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg 1998; 228: 228-238
24. Noda S, Norton JA, Jensen RT, Gay WA Jr. Surgical resection of intracardiac gastrinoma. Ann Thorac Surg 1999; 67: 532-533
25. Doppman JL, Miller DL, Chang R, Shawker TH, Gorden P, Norton JA. Insulinomas: localization with selective intraarterial injection of calcium. Radiology 1991; 178: 237-241
26. Krenning EP, Kwekkeboom DJ, Oei HY, de Jong RJ, Dop FJ, Reubi JC, Lamberts SW. Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. An overview of European results. Ann N Y Acad Sci 1994; 733: 416-424
27. Jensen RT. Zollinger-Ellison syndrome. In: Doherty GM, Skogseid B, editors. Surgical Endocrinology: Clinical syndromes. Philadelphia: Lippincott William & Wilkins, 2001: 291-343
28. Portela-Gomes GM, Stridsberg M, Grimelius L, Rorstad O, Janson ET. Differential expression of the five somatostatin receptor subtypes in human benign and malignant insulinomas-predominance of receptor subtype 4. Endocr Pathol 2007; 18: 79-85
29. Grant CS, van Heerden J, Charboneau JW, James EM, Reading CC. Insulinoma. The value of intraoperative ultrasonography. Arch Surg 1988; 123: 843-848
30. Kato M, Imamura M, Hosotani R, Shimada Y, Doi R, Itami A, Komoto I, Kosaka M TT, Konishi J. Curative resection of microgastrinomas based on the intraoperative secretin test. World J Surg 2000; 24: 1425-1430
31. Imamura M. Surgical Treatment. In: Beger HG, Warshaw A, Buchler M, Kozarek R, Lerch MM, Neoptolemos J, Shiratori K, Whicomb D, editors. The Pancreas. 2nd edition. Massachusetts: Blackwell Publishing, 2008: 818-822
32. Norton JA, Fraker DL, Alexander HR, Gibril F, Liewehr DJ, Venzon DJ, Jensen RT. Surgery increases survival in patients with gastrinoma. Ann Surg 2006; 244: 410-419
33. Goretzki PE, Röher HD. Islet tumors. In: Beger HG, Warshaw A, Buchler M, Kozarek R, Lerch MM, Neoptolemos J, Shiratori K, Whicomb D, editors. The Pancreas. 2nd edition. Massachusetts: Blackwell Publishing, 2008: 794-801
34. Gibril F, Venzon DJ, Ojeaburu JV, Bashir S, Jensen RT. Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form. J Clin Endocrinol Metab 2001; 86: 5282-5293
35. Jensen RT, Berna MJ, Bingham DB, Norton JA. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer 2008; 113: 1807-1843
36. Goudet P, Murat A, Binquet C, Cardot-Bauters C, Costa A, Ruszniewski P, Niccoli P, Ménégaux F, Chabrier G, Borson-Chazot F, Tabarin A, Bouchard P, Delemer B, Beckers A, Bonithon-Kopp C. Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg 2010; 34: 249-255
37. Thompson NW. Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease. Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both. J Intern Med 1998; 243: 495-500
38. Lairmore TC, Piersall LD, DeBenedetti MK, Dilley WG, Mutch MG, Whelan AJ, Zehnbauer B. Clinical genetic testing and early surgical intervention in patients with multiple endocrine neoplasia type 1 (MEN 1). Ann Surg 2004; 239: 637-645; discussion 645-647
39. O'Riordain DS, O'Brien T, van Heerden JA, Service FJ, Grant CS. Surgical management of insulinoma associated with multiple endocrine neoplasia type I. World J Surg 1994; 18: 488-493; discussion 493-494
40. Pipeleers-Marichal M, Donow C, Heitz PU, Klöppel G. Pathologic aspects of gastrinomas in patients with Zollinger-Ellison syndrome with and without multiple endocrine neoplasia type I. World J Surg 1993; 17: 481-488
41. Imamura M, Kanda M, Takahashi K, Shimada Y, Miyahara T, Wagata T, Hashimoto M, Tobe T, Soga J. Clinicopathological characteristics of duodenal microgastrinomas. World J Surg 1992; 16: 703-709; discussion 709-710
42. Bartsch DK, Fendrich V, Langer P, Celik I, Kann PH, Rothmund M. Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg 2005; 242: 757-764, discussion 764-766
43. Imamura M, Komoto I, Doi R. Resection surgery for gastrinomas in patients with MEN 1 and ZES guided by selective arterial secretagogue injection test. World J Surg 2009; 33 Suppl 1: S67
44. Imamura M, Komoto I, Doi R, Onodera H, Kobayashi H, Kawai Y. New pancreas-preserving total duodenectomy technique. World J Surg 2005; 29: 203-207
45. Klöppel G, Anlauf M, Perren A. Endocrine precursor lesions of gastroenteropancreatic neuroendocrine tumors. Endocr Pathol 2007; 18: 150-155
46. Steinmüller T, Kianmanesh R, Falconi M, Scarpa A, Taal B, Kwekkeboom DJ, Lopes JM, Perren A, Nikou G, Yao J, Delle Fave GF, O'Toole D. Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2008; 87: 47-62
47. Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, Blumgart LH. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000; 190: 432-445
48. Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg 1998; 187: 88-92; discussion 92-93
49. Bettini R, Boninsegna L, Mantovani W, Capelli P, Bassi C, Pederzoli P, Delle Fave GF, Panzuto F, Scarpa A, Falconi M. Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. Ann Oncol 2008; 19: 903-908
50. Bilchik AJ, Rose DM, Allegra DP, Bostick PJ, Hsueh E, Morton DL. Radiofrequency ablation: a minimally invasive technique with multiple applications. Cancer J Sci Am 1999; 5: 356-361
51. Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology 2003; 226: 441-451
52. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D, Van Cutsem E, Kulke MH, Hobday TJ, O'Dorisio TM, Shah MH, Cadiot G, Luppi G, Posey JA, Wiedenmann B. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010; 28: 69-76
53. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A, Meric-Bernstam F. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low-to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008; 26: 4311-4318
54. Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, Dunder K, Kozlovacki G, Orlefors H, Sigurd M, Oberg K, Eriksson B, Skogseid B. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007; 13: 2986-2991